231 related articles for article (PubMed ID: 11676303)
1. Calcineurin inhibitors and post-transplant hyperlipidaemias.
Moore R; Hernandez D; Valantine H
Drug Saf; 2001; 24(10):755-66. PubMed ID: 11676303
[TBL] [Abstract][Full Text] [Related]
2. Post-transplant diabetes mellitus. The role of immunosuppression.
Jindal RM; Sidner RA; Milgrom ML
Drug Saf; 1997 Apr; 16(4):242-57. PubMed ID: 9113492
[TBL] [Abstract][Full Text] [Related]
3. Calcineurin inhibitors in renal transplantation: what is the best option?
Tanabe K
Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
[TBL] [Abstract][Full Text] [Related]
4. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
5. Management of hyperlipidaemia associated with heart transplantation.
Wenke K
Drugs; 2004; 64(10):1053-68. PubMed ID: 15139786
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for and management of post-transplantation cardiovascular disease.
Fellström B
BioDrugs; 2001; 15(4):261-78. PubMed ID: 11437691
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus: a further update of its use in the management of organ transplantation.
Scott LJ; McKeage K; Keam SJ; Plosker GL
Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
9. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.
Boots JM; Christiaans MH; van Hooff JP
Drugs; 2004; 64(18):2047-73. PubMed ID: 15341497
[TBL] [Abstract][Full Text] [Related]
10. Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
Valantine H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S187-93. PubMed ID: 15093804
[TBL] [Abstract][Full Text] [Related]
11. Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients.
Asberg A
Drugs; 2003; 63(4):367-78. PubMed ID: 12558459
[TBL] [Abstract][Full Text] [Related]
12. What is the calcineurin inhibitor of choice for pediatric renal transplantation?
Kari JA; Trompeter RS
Pediatr Transplant; 2004 Oct; 8(5):437-44. PubMed ID: 15367278
[TBL] [Abstract][Full Text] [Related]
13. Cryptococcus neoformans isolates from transplant recipients are not selected for resistance to calcineurin inhibitors by current immunosuppressive regimens.
Blankenship JR; Singh N; Alexander BD; Heitman J
J Clin Microbiol; 2005 Jan; 43(1):464-7. PubMed ID: 15635017
[TBL] [Abstract][Full Text] [Related]
14. Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets.
Adams H; Campidelli C; Dirnhofer S; Pileri SA; Tzankov A
Expert Opin Ther Targets; 2009 Oct; 13(10):1137-45. PubMed ID: 19705967
[TBL] [Abstract][Full Text] [Related]
15. Calcineurin inhibitors in pediatric renal transplant recipients.
Filler G
Paediatr Drugs; 2007; 9(3):165-74. PubMed ID: 17523697
[TBL] [Abstract][Full Text] [Related]
16. Post-transplant hyperlipidaemia.
Jindal RM
Postgrad Med J; 1997 Dec; 73(866):785-93. PubMed ID: 9497947
[TBL] [Abstract][Full Text] [Related]
17. Strategies for minimizing hyperlipidemia after cardiac transplantation.
Kirklin JK; Benza RL; Rayburn BK; McGiffin DC
Am J Cardiovasc Drugs; 2002; 2(6):377-87. PubMed ID: 14727953
[TBL] [Abstract][Full Text] [Related]
18. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
19. Post-transplant diabetes mellitus: risk reduction strategies in the elderly.
Duclos A; Flechner LM; Faiman C; Flechner SM
Drugs Aging; 2006; 23(10):781-93. PubMed ID: 17067182
[TBL] [Abstract][Full Text] [Related]
20. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
Agarwal SK; Bhowmik D; Mahajan S; Bagchi S
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
